Sakata Y, Suzuki H, Satoh T, Kawatsu S, Tanabe K, Okamoto K, Takagi S, Komatsu Y, Kawakami K, Yoshida Y
Gan To Kagaku Ryoho. 1986 Jul;13(7):2415-8.
Sulpiride, which has been utilized as an antipeptic ulcer and antidepressant in Japan, is one of the dopamine antagonists, and is considered to have anti vomiting activity. We designed a comparative controlled study of Sulpiride and Domperidone, against nausea and vomiting during cancer chemotherapy. A total of 69 cases were entered into this study, 34 cases being treated with Sulpiride at a dose of 100 mg i.v. or i.m. (S group), and 35 cases being treated with Domperidone at a dose of 10 mg i.v. (D group), before and after chemotherapy. Three cases from the S group and 4 cases from the D group were excluded from this study because of differences in the administration schedule. There was no difference in patient characteristics between the two groups, such as age, sex, original disease and antitumor agents. According to our criteria 27 of 31 cases in the S group showed effectiveness of the agent against nausea and vomiting (87%), while in the D group, 24 cases showed effectiveness (77%). There was no statistical difference between them, and no side effects were found in either group.
舒必利在日本已被用作抗消化性溃疡药和抗抑郁药，它是多巴胺拮抗剂之一，被认为具有止吐活性。我们设计了一项舒必利与多潘立酮对比的对照研究，用于治疗癌症化疗期间的恶心和呕吐。本研究共纳入69例患者，其中34例接受舒必利治疗，静脉注射或肌肉注射剂量为100mg（S组），35例接受多潘立酮治疗，静脉注射剂量为10mg（D组），在化疗前后进行。由于给药方案不同，S组有3例和D组有4例被排除在本研究之外。两组患者的特征如年龄、性别、原发疾病和抗肿瘤药物等方面无差异。根据我们的标准，S组31例中有27例显示该药对恶心和呕吐有效（87%），而D组有24例显示有效（77%）。两组之间无统计学差异，且两组均未发现副作用。
